Maravai LifeSciences (MRVI) vs Schrodinger (SDGR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Maravai LifeSciences (MRVI) has outperformed Schrodinger (SDGR) over the past year, gaining 124.5% versus a gain of 35.4%. Over five years, SDGR leads with a -50.7% price change compared with -80.0% for MRVI. Maravai LifeSciences is the larger company by market cap ($2.75 billion vs $2.04 billion), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MRVI | SDGR |
|---|---|---|
| Share price | $7.43 | $27.29 |
| Market cap | $2.75B | $2.04B |
| 1-day change | -5.35% | -5.57% |
| YTD return | +128.62% | +52.63% |
| 1-year return | +124.47% | +35.37% |
| 5-year return | -79.97% | -50.70% |
| EPS (TTM) | $-0.53 | $-0.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $185.74M | — |
| Revenue growth (YoY) | -28.34% | — |
| Net income (latest FY) | $-130.77M | — |
| Gross margin | 18.30% | — |
| Operating margin | -115.89% | — |
| Net margin | -70.41% | — |
| 52-week high | $9.42 | $33.78 |
| 52-week low | $2.55 | $10.95 |
| Distance from 52-week high | -21.13% | -19.21% |
| Analyst consensus | buy | none |
| Avg. price target upside | +5.38% | -21.47% |
| Average volume | 3.31M | 1.69M |
| Shares outstanding | 148.99M | 65.64M |
| Employees | 415 | 850 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MRVI has outperformed SDGR by 89.1 percentage points over the past year.
About Maravai LifeSciences
MRVI stock →Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS.
Health Care · Biotechnology: Pharmaceutical Preparations · 415 employees
About Schrodinger
SDGR stock →Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery.
Health Care · Biotechnology: Pharmaceutical Preparations · 850 employees
MRVI vs SDGR FAQ
Which is bigger, Maravai LifeSciences or Schrodinger?
Maravai LifeSciences (MRVI) is larger, with a market capitalization of $2.75B compared with $2.04B for Schrodinger (SDGR).
Which stock has performed better over the past year, MRVI or SDGR?
MRVI returned +124.47% over the past 12 months, compared with +35.37% for SDGR (price return, excluding dividends). Past performance does not predict future results.
Are Maravai LifeSciences and Schrodinger in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.